Kiniksa Pharmaceuticals International, plc - Class A — Cash Flow (NASDAQ:KNSA) | MetaTrader

Open full chart

Financials

Overview Relatórios Statistics Dividends

Quarterly Annual

Cash from operating activities -136.53 M-126.3 M5.81 M13.3 M25.69 M137.99 M 137.99 M Cash from investing activities -23.44 M128.63 M-8.08 M-29.56 M37.67 M-188.99 M -188.99 M Cash from financing activities 227.09 M5.88 M2.52 M1.5 M12.27 M33.02 M 33.02 M Free cash flow -136.81 M-146.71 M5.7 M13.17 M25.41 M136.42 M 136.42 M

Notícias

Drug Stocks Lead Eight Hot New Names Onto IBD 50 List, Big Cap 20 And More

ASML, With Unique AI Tech, Leads 8 Hot Growth Stocks Joining IBD's Top Screens

Nurix Therapeutics Stock Sees RS Rating Jump To 82

Construction Star Leads 11 Hot Stocks To Various Best Growth Lists like IBD 50, Sector Leaders

Lucro da Kiniksa Pharma veio abaixo das projeções por $0,18; receita supera estimativas

Kiniksa Pharma earnings missed by $0.18, revenue topped estimates

Wedbush eleva preço-alvo das ações da Kiniksa para US$ 53 com base nas perspectivas de lançamento

Wedbush raises Kiniksa stock price target to $53 on launch outlook

Kiniksa Pharmaceuticals International, plc 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:KNSA) 2026-02-24

Kiniksa Q4 2025 slides: ARCALYST drives 62% growth, profitability

Resultados da Kiniksa em foco enquanto medicamento para doença rara impulsiona crescimento

Kiniksa earnings in focus as rare disease drug fuels growth